A practical guide to request humoral autoimmunity markers and genetic tests in diabetes mellitus

Authors

  • Silvina Valdez National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina
  • Miguel Ángel Alonso Amorín Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina
  • María Fernanda Álvarez Yuseff General Acute Hospital Dr. Cosme Argerich, Autonomous City of Buenos Aires, Argentina
  • Luz Andreone National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina
  • Gloria Cerrone National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina
  • Iris Mabel Ledesma Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina
  • Alejandra Matejic University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina
  • Laura Pelayo Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina
  • Marcelo Javier Pelone National Council for Scientific and Technical Research (CONICET), Buenos Aires, Argentina
  • Aldana Trabucchi National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina
  • Gustavo Daniel Frechtel Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v56i2Sup.531

Keywords:

genetic, autoantibodies, classification, clinical diagnosis

Abstract

Diabetes mellitus (DM) is a heterogeneous disease, with diverse clinical phenotypes, all with hyperglycemia. Historically, four factors have been used to identify this diversity: the age at onset, the severity of the disease, that is, the degree of loss of beta cell function and insulin resistance, and the presence of circulating autoantibodies.
Currently, the parameters used to classify the different types of DM make it difficult to diagnose and treat patients. The different clinical manifestations require an accurate diagnosis to achieve an effective therapeutic approach through the use of immunogenetics and clinical biochemistry.
This practical guide aims to accurately classify the often uncertain clinical presentations within the two main types of diabetes.

Author Biographies

Silvina Valdez, National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina

PhD from the University of Buenos Aires (UBA); Adjunct Professor, Faculty of Pharmacy and Biochemistry (UBA); Independent Researcher; Coordinator of the Genetics, Immunology and Prevention Committee of the Argentine Diabetes Society (SAD), Institute of Diabetes Studies Humoral Immunity Prof. Ricardo Aníbal Margni (IDEHU)

Miguel Ángel Alonso Amorín, Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina

Former Physician and Associate Researcher at the Diabetes Division of the José de San Martín Hospital de Clínicas, University of Buenos Aires (UBA); current Consultant of the Diabetes Division of the José de San Martín Hospital de Clínicas

María Fernanda Álvarez Yuseff, General Acute Hospital Dr. Cosme Argerich, Autonomous City of Buenos Aires, Argentina

Endocrinology Plant Physician

Luz Andreone, National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina

PhD from the University of Buenos Aires (UBA); Associate Researcher of the National Council for Scientific and Technical Research, Immuno-Endocrinology, Diabetes and Metabolism Laboratory, Translational Medicine Research Institute (IIMT, CONICET-Universidad Austral)

Gloria Cerrone, National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina

Doctor of the University of Buenos Aires (UBA); Adjunct Professor of the Chair of Genetics, Faculty of Pharmacy and Biochemistry, UBA; Researcher of the National Council for Scientific and Technical Research, Institute of Immunology, Genetics and Metabolism (INIGEM)

Iris Mabel Ledesma, Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina

Specialist in Clinical Medicine and Nutrition; Associate Professor at the Faculty of Medicine, University of Buenos Aires (UBA); Ad Honorem Staff Physician, Nutrition Service of the Hospital de Clínicas José de San Martín

Alejandra Matejic, University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina

Adjunct Professor, Chair of Periodontics, Faculty of Dentistry; Master in Periodontology, Faculty of Dentistry; Secretary of the Genetics, Immunology and Prevention Committee of the Argentine Diabetes Society (SAD)

Laura Pelayo, Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina

Physician graduated from the University of Buenos Aires (UBA); Specialist in Nutrition, Fundación Barceló University; Honorary Physician

Marcelo Javier Pelone, National Council for Scientific and Technical Research (CONICET), Buenos Aires, Argentina

Doctor of the National University of La Plata (UNLP), Researcher National Council for Scientific and Technical Research, Laboratory of Immuno-Endocrinology, Diabetes and Metabolism, Institute for Research in Translational Medicine (IIMT) CONICET-Universidad Austral; Professor of the Faculty of Biomedical Sciences, Austral University

Aldana Trabucchi, National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina

PhD from the University of Buenos Aires (UBA), Faculty of Pharmacy and Biochemistry, Chair of Immunology; Assistant Researcher, Institute of Humoral Immunity Studies Prof. Ricardo Aníbal Margni (IDEHU)

Gustavo Daniel Frechtel, Hospital de Clínicas José de San Martín, Autonomous City of Buenos Aires, Argentina

Doctor of the University of Buenos Aires (UBA); Professor of the Department of Medicine, Nutrition orientation, Faculty of Medicine; Head of the Nutrition Division Hospital de Clínicas; Clinical Researcher, National Council for Scientific and Technical Research (CONICET)

References

I. Adler A, Bennett P, Colagiuri-Chair S, Gregg E, et al. Reprint of classification of diabetes mellitus. Diabetes Res Clin Pract 2021;108972.

II. Cerrone GE, Valdez S, Poskus E, Frechtel GD. Bases inmunogenéticas de la diabetes autoinmune: aplicación a la fisiopatología, clínica y tratamiento. Fisiopatología molecular y clínica endocrinológica. 2015. Editores: R. Calandra, M. Barontini. Eli Lily.

III. Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. The Lancet. Diabetes & Endocrinology 2018;6(2):122-129.

IV. Genuth SM, Palmer JP, Nathan DM. Classification and diagnosis of diabetes. In: Cowie CC (Eds.) et. al. Diabetes in America. (3rd ed.), 2018. National Institute of Diabetes and Digestive and Kidney Diseases (US).

V. Sperling MA, Wolfsdorf JI, Menon RK, Tamborlane WV, Maahs D, Battelino T, Phillip M. Diabetes Mellitus, Editor(s): Mark A. Sperling, Sperling Pediatric Endocrinology (Fifth Edition), Elsevier; 2021:814-883.

VI. Wang Z, Zhang J, Xu H, Chen L, Dove A. Development and validation of a prevalence model for latent autoimmune diabetes in adults (LADA) among patients first diagnosed with type 2 diabetes mellitus (T2DM). Medical science monitor: International Medical Journal of Experimental and Clinical Research 2021;27:e932725.

VII. Valdez S, Poskus E. Autoimmune diabetes mellitus: the importance of autoantibodies for disease prediction and diagnostic support. Current Immunology Reviews 2010;6: 299-313.

VIII. Trabucchi A, Faccinetti NI, Guerra LL, Puchulu F, Frechtel GD, Poskus E, Valdez SN. Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. Autoimmunity 2012; 45(2):137-142.

IX. Mauvais-Jarvis F, Sobngwi E, Porcher R, Riveline J-P, Kevorkian JP, Vaisse C, et al. Ketosis-prone type 2 diabetes in patients of Sub Saharan African origin. Clinical pathophysiology and natural history of β-cell dysfunction and insulin resistance. Diabetes 2004;53:645-653.

X. Sánchez-Caballero L, Gorgogietas V, Arroyo MN, Igoillo-Esteve M. Molecular mechanisms of β-cell dysfunction and death in monogenic forms of diabetes. International Review of Cell and Molecular Biology 2021;359:139-256.

XI. Nkonge KM, Nkonge DK, Nkonge TN. The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY). Clinical Diabetes and Endocrinology;2020,6(1):20.

XII. Consultado:

XIII. http://www.revistabioanalisis.com/images/flippingbook/Rev32%20n/nota1.pdf

XIV. de Dios A, López A, Frechtel G. Clínica y tratamiento de la diabetes tipo MODY. Revista de la Sociedad Argentina de Diabetes 2014;48 (3):130-138.

XV. Oliveira SC, Neves JS, Pérez A, Carvalho D. Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management. Endocrinología, Diabetes y Nutrición 2020;67(2):137-147. doi: 10.1016/j.endinu.2019.07.012.

Published

2022-08-01

How to Cite

Valdez, S., Alonso Amorín, M. Ángel, Álvarez Yuseff, M. F., Andreone, L., Cerrone, G., Ledesma, I. M., Matejic, A., Pelayo, L., Pelone, M. J., Trabucchi, A., & Frechtel, G. D. (2022). A practical guide to request humoral autoimmunity markers and genetic tests in diabetes mellitus. Journal of the Argentine Society of Diabetes, 56(2Sup), 15–18. https://doi.org/10.47196/diab.v56i2Sup.531

Issue

Section

Recommendations

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 > >>